Mesalamine Market Likely to Experience a Tremendous Growth in Future by Report Analysis 2020-2025 | Allergan, Salix, Nogra, AstraZeneca, Abbvie, Takeda, Janssen, Pfizer, Ferring, Boehringer

Mesalamine Market 2020 Global Industry research report studies latest Mesalamine industry aspects market size, share, trends, growth, business overview and Mesalamine industry scenario during the forecast period (2020-2025).

Global Mesalamine Market overview:

Mesalamine is used to treat ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum) and also to maintain improvement of ulcerative colitis symptoms. Mesalamine is in a class of medications called anti-inflammatory agents. The Global Mesalamine Market is segmented on the basis of Product Type, Application, End Use Industry and Region. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/240112 .

On the Basis of Product Type segment, the Mesalamine Market is sub segmented into Capsule and Tablets. Based on End Use Industry segment, the Mesalamine Market is segmented as Adult and Children. There are several manufacturers of Mesalamine in Europe and North America. In North America, the demand for Mesalamine is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Mesalamine Market Report 2020” @ https://www.businessindustryreports.com/buy-now/240112/single .

Top Industry News:

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease on 08 October, 2020 -- Takeda Pharmaceutical Company Limited and Arrowhead Pharmaceuticals Inc. today announced a collaboration and licensing agreement to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD). ARO-AAT is a potential first-in-class therapy designed to reduce the production of mutant alpha-1 antitrypsin protein, the cause of AATLD progression.

Under the terms of the agreement, Takeda and Arrowhead will co-develop ARO-AAT which, if approved, will be co-commercialized in the United States under a 50/50 profit-sharing structure. Outside the U.S., Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with Arrowhead eligible to receive tiered royalties of 20-25% on net sales. Arrowhead will receive an upfront payment of $300 million and is eligible to receive potential development, regulatory and commercial milestones up to $740 million. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S.

“AAT-associated liver disease is a devastating condition for which there are no approved therapies. With its RNAi-based mechanism of action, ARO-AAT has the potential to treat the underlying cause of AATLD, thereby helping patients avoid the need for liver transplantation and associated co-morbidities,” said Asit Parikh, M.D., Ph.D., Head, Gastroenterology Therapeutic Area Unit at Takeda. “We are excited to collaborate with Arrowhead to bring forward this exciting late-stage liver asset for the Alpha-1 community as part of our growing GI portfolio.”

“Takeda’s global presence and experience with payers and regulators in the rare disease and GI therapy space, combined with its long history serving the Alpha-1 community make it the ideal partner for ARO-AAT. It is well-positioned to work with the patient and medical community to help meet the severe unmet need of patients with Alpha-1 liver disease,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. “This agreement also supports our strategy of using partnering selectively to continue to invest in our Targeted RNAi Molecule (TRiM) platform and the growing pipeline of RNAi therapeutics targeting diverse tissue types, while focusing our commercial organization on opportunities in two key areas of cardiometabolic and pulmonary.”

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/240112 .

Major Key Players:

Some of the Mesalamine Market manufacturers involved in the market are Allergan, Salix Pharmaceuticals, Nogra Pharma, AstraZeneca, Abbvie, Takeda, Janssen (Johnson & Johnson), Pfizer, Ferring, Boehringer Ingelheim, Cosmo Pharmaceuticals, Teva, Mylan, Sandoz Mesalamine, Tillotts Pharma, Chiesi Farmaceutici, Dr Falk Pharma, Cipla, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical, Shanghai Sine Promod Pharmaceutical in World, effective mergers are some of the strategies adopted by the Mesalamine Market manufacturers. New product launches and continuous technological innovations are the Mesalamine Market strategies adopted by the major players.

Table of Contents:

1 Mesalamine Product Definition
2 Global Mesalamine Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Mesalamine Shipments
2.2 Global Manufacturer Mesalamine Business Revenue
2.3 Global Mesalamine Market Overview
3 Manufacturer Mesalamine Business Introduction
3.1 Allergan Mesalamine Business Introduction
3.1.1 Allergan Mesalamine Shipments, Price, Revenue and Gross profit 2014-2019
3.1.2 Allergan Mesalamine Business Distribution by Region
3.1.3 Allergan Interview Record
3.1.4 Allergan Mesalamine Business Profile
3.1.5 Allergan Mesalamine Product Specification
3.2 Salix Pharmaceuticals Mesalamine Business Introduction
3.2.1 Salix Pharmaceuticals Mesalamine Shipments, Price, Revenue and Gross profit 2014-2019
3.2.2 Salix Pharmaceuticals Mesalamine Business Distribution by Region
3.2.3 Interview Record
3.2.4 Salix Pharmaceuticals Mesalamine Business Overview
3.2.5 Salix Pharmaceuticals Mesalamine Product Specification
3.3 Nogra Pharma Mesalamine Business Introduction
3.3.1 Nogra Pharma Mesalamine Shipments, Price, Revenue and Gross profit 2014-2019
3.3.2 Nogra Pharma Mesalamine Business Distribution by Region
3.3.3 Interview Record
3.3.4 Nogra Pharma Mesalamine Business Overview
3.3.5 Nogra Pharma Mesalamine Product Specification
3.4 AstraZeneca Mesalamine Business Introduction
3.5 Abbvie Mesalamine Business Introduction
3.6 Takeda Mesalamine Business Introduction

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.